WINTER IS COMING

Weight Management

1 / 7

Peptides Line

Adipotide

Name: Adipotide
Brand: Peptalon
SKU: PE-0263-01-2
Availability: InStock
Rating: 4.8 (127 reviews)

Adipotide is a research peptide designed to selectively target and destroy fat cell blood supply, leading to apoptosis (cell death) of fat tissue. Unlike traditional fat burners, it works independently of metabolism or stimulant pathways, making it especially promising for reducing visceral and hard-to-target fat areas. Ideal for advanced users aiming at body recomposition and precise fat reduction without systemic overstimulation.

From AED 280.00

format:

Key Ingredients

Adipotide (FTP-11)

Fat Burning Support

Fat Metabolism Support

Not sure about the right dosage?

Use our Peptide Dosage Calculator for optimal application

Main Information

Adipotide is an experimental compound that offers an innovative approach to the treatment of obesity and related metabolic disorders through its targeted action on adipose tissue. While research is currently still in thepreclinical phase, animal studies show promising results in terms of fat cell apoptosis (programmed cell death) and an associated significant reduction in body fat mass.Since Adipotide, unlike classic GLP-1 receptor agonists, does not work via appetite reduction but via direct destruction of fat cells, it could be an alternative for patients for whom hormone-based weight management therapies are not effective.

Scientific Background

Adipotide (also known as FTPP, or Prohibitin-targeting peptide 1) is an experimental fat-loss agent originally developed by scientists researching new ways to treat obesity and metabolic disorders. It represents a unique approach: instead of affecting appetite or hormones, Adipotide works by cutting off the blood supply to fat cells, specifically targeting the vasculature (blood vessels) of white adipose tissue.

This mechanism was pioneered by researchers at the MD Anderson Cancer Center and the University of Texas, who were exploring the use of vascular-targeting peptides. Adipotide binds to proteins such as prohibitin and annexin A2 found on the surface of blood vessels that nourish white fat tissue. Once bound, it induces apoptosis (programmed cell death) by depriving fat cells of oxygen and nutrients. Over time, this leads to the shrinkage and loss of fat tissue, particularly in visceral and subcutaneous fat depots.

Scientific Evidence

One of the most notable preclinical studies was published in Science Translational Medicine in 2011: In this study, obese rhesus monkeys were treated with Adipotide daily for four weeks. The results showed:

An average 11% reduction in body weight

Up to 39% reduction in white fat mass

Improved insulin sensitivity and lower fasting blood glucose

No significant appetite suppression — weight loss occurred independently of reduced food intake

Importantly, these effects were reversible after discontinuation of treatment, and the monkeys showed no significant damage to other organs when properly monitored.These findings highlighted Adipotide’s potential as a targeted fat-loss therapy, especially for visceral fat, which is closely linked to metabolic diseases such as type 2 diabetes and cardiovascular risk.

References

Barnhart K. et al. (2011): “A Peptide-Based Targeting Strategy for Visceral Adipose Tissue and the Induction of Sustained Weight Loss”.Sci Transl Med 3, 108ra112.DOI: 10.1126/scitranslmed.3002621

Usage Instructions

For further Information how to prepare and use your Adipotide Vial for Subcutaneous Injection please check the Instructions in the Product Leaflet.

Here you can find the most important steps for preparation shortly summarized :

Before use, check the solution by swinging the vial or syringe up and down once or twice. Do not use the solution if it is cloudy or has changed color.Adipotide® is designed for use with insulin syringes of any type up to 16mm in length.
Always use a new syringe or needle for each injection.
Always change the site of injection to avoid damaging your skin.
To ensure that you receive the full dose and do not inject air, check each new insulin syringe to see if the solution comes out properly before the first injection. Do not use the syringe if a drop of growth hormone does not appear at the tip of the needle (see pages 10 to 11, steps E to G in Product Leaflet).
Do not share your syringe of Adipotide® with anyone else.

Dosage Information

For general obesity management, experimental protocols typically use 250 to 500 micrograms (µg) per day via subcutaneous injection, with a recommendation to start at the lower end and adjust gradually based on individual tolerability.

In off-label use focused on targeted fat reduction, such as for stubborn fat deposits, 500 to 750 µg per day may be considered — though this is generally reserved for experienced users due to an increased risk of localized side effects. In more aggressive, high-dose approaches aimed at treating severe obesity, daily doses up to 1 mg have been used experimentally, though such protocols require close medical monitoring due to higher systemic impact and potential risk.

Adipotide is typically administered via subcutaneous injection, preferably in the morning on an empty stomach to enhance fat-targeting efficiency. A gradual dosing approach is strongly advised: users should begin with a low dose and titrate upward slowly to minimize adverse reactions such as nausea, dizziness, or kidney stress.

Treatment is best structured in cycles of 4 to 6 weeks, followed by a break phase to allow the body to reset and to monitor outcomes and any emerging side effects. This cyclical strategy may help reduce long-term risks and improve overall therapy control.

Important Warnings

Because Adipotide works by disrupting the blood supply to fat cells, it leads to the breakdown and clearance of adipose tissue. This process places certain physiological systems under stress, making regular monitoring essential to detect potential risks early and ensure safe application.Kidney function is a primary concern, as the breakdown of fat cells can increase the burden on renal pathways due to the accumulation of waste products. Key markers such as creatinine and estimated glomerular filtration rate (eGFR) should be checked once weekly during the first 4 weeks of treatment. Similarly, liver enzymes — particularly ALT, AST, and GGT — should be assessed every two weeks to monitor for any disturbances in hepatic fat metabolism.

Monitoring cardiovascular parameters is also advised, since the sudden metabolic shift caused by fat loss may elevate blood pressure or heart rate in sensitive individuals. Regular self-measurement at home is recommended. In people with insulin resistance or diabetes, blood glucose levels should be tracked daily, as Adipotide may influence insulin sensitivity and glucose homeostasis.To assess the effectiveness of the treatment, users should track body weight and body fat percentage using a body composition scale once per week. Additionally, because fat cell apoptosis can cause fluid shifts and increased excretion, users should monitor hydration status and electrolyte balance, including sodium and potassium levels, through blood work every 2 to 4 weeks.

Important Considerations and Safety Notes

Check individual tolerance: As Adipotide remains in the experimental stage, a gradual introduction and frequent monitoring are critical. Reactions may vary significantly between individuals.
Ensure proper hydration: Fat breakdown increases water excretion. To prevent dehydration and electrolyte imbalances, a fluid intake of 3–4 liters per day is recommended throughout the treatment cycle.
Not suitable for pregnancy or breastfeeding: Adipotide should not be used by pregnant or breastfeeding women, due to unknown effects on hormonal balance and fetal development.
Not a substitute for lifestyle changes: While Adipotide facilitates fat cell destruction, it is not a replacement for proper nutrition and exercise. Long-term success still requires adherence to a healthy lifestyle.

Frequently Asked Questions

What Others Have Selected

AED 160.00

AED 190.00

AED 190.00

AED 220.00

AED 190.00

AED 230.00

AED 300.00

AED 250.00

AED 190.00

AED 190.00

AED 250.00

Knowledge that might interest you

Detox and Recovery: What to Stack Post-Adipotide for Kidney Protection

Adipotide’s appeal lies in its precision — it targets the blood vessels that feed white fat cells, gradually leading to fat cell death. But with that ...

Safe Dosing & Cycle Timing of Adipotide

Adipotide is not your average fat loss compound. It doesn’t stimulate thermogenesis, manipulate hormone levels, or increase metabolic rate. Instead, ...

The Science Behind Vascular Disruption in White Adipose Tissue

A New Way to Target Fat For decades, the pursuit of fat loss has revolved around the same physiological levers: reduce caloric intake, increase energy...

For further Information how to prepare and use your Adipotide Vial for Subcutaneous Injection please check the Instructions in the Product Leaflet.

Here you can find the most important steps for preparation shortly summarized :

Before use, check the solution by swinging the vial or syringe up and down once or twice. Do not use the solution if it is cloudy or has changed color.Adipotide® is designed for use with insulin syringes of any type up to 16mm in length.
Always use a new syringe or needle for each injection.
Always change the site of injection to avoid damaging your skin.
To ensure that you receive the full dose and do not inject air, check each new insulin syringe to see if the solution comes out properly before the first injection. Do not use the syringe if a drop of growth hormone does not appear at the tip of the needle (see pages 10 to 11, steps E to G in Product Leaflet).
Do not share your syringe of Adipotide® with anyone else.

Dosage Information

For general obesity management, experimental protocols typically use 250 to 500 micrograms (µg) per day via subcutaneous injection, with a recommendation to start at the lower end and adjust gradually based on individual tolerability.

In off-label use focused on targeted fat reduction, such as for stubborn fat deposits, 500 to 750 µg per day may be considered — though this is generally reserved for experienced users due to an increased risk of localized side effects. In more aggressive, high-dose approaches aimed at treating severe obesity, daily doses up to 1 mg have been used experimentally, though such protocols require close medical monitoring due to higher systemic impact and potential risk.

Adipotide is typically administered via subcutaneous injection, preferably in the morning on an empty stomach to enhance fat-targeting efficiency. A gradual dosing approach is strongly advised: users should begin with a low dose and titrate upward slowly to minimize adverse reactions such as nausea, dizziness, or kidney stress.

Treatment is best structured in cycles of 4 to 6 weeks, followed by a break phase to allow the body to reset and to monitor outcomes and any emerging side effects. This cyclical strategy may help reduce long-term risks and improve overall therapy control.

Important Warnings

Important Considerations and Safety Notes

Check individual tolerance: As Adipotide remains in the experimental stage, a gradual introduction and frequent monitoring are critical. Reactions may vary significantly between individuals.
Ensure proper hydration: Fat breakdown increases water excretion. To prevent dehydration and electrolyte imbalances, a fluid intake of 3–4 liters per day is recommended throughout the treatment cycle.
Not suitable for pregnancy or breastfeeding: Adipotide should not be used by pregnant or breastfeeding women, due to unknown effects on hormonal balance and fetal development.
Not a substitute for lifestyle changes: While Adipotide facilitates fat cell destruction, it is not a replacement for proper nutrition and exercise. Long-term success still requires adherence to a healthy lifestyle.

Featured Categories

Browse All Categories

Featured Product

Featured Collections

Browse All Collections

Discover Lines

Featured Knowledge

Browse All Knowledge

Expert Knowledge

Adipotide